IRIS
MILANI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.041
AS - Asia 3.106
EU - Europa 2.296
SA - Sud America 475
AF - Africa 185
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.111
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.930
CN - Cina 1.080
SG - Singapore 833
IE - Irlanda 665
HK - Hong Kong 430
VN - Vietnam 367
BR - Brasile 348
RU - Federazione Russa 325
DE - Germania 267
IT - Italia 233
FI - Finlandia 215
FR - Francia 164
ZA - Sudafrica 129
GB - Regno Unito 108
IN - India 104
SE - Svezia 64
CA - Canada 62
UA - Ucraina 60
BD - Bangladesh 47
JP - Giappone 38
AR - Argentina 37
PL - Polonia 36
MX - Messico 35
IQ - Iraq 30
ES - Italia 29
TR - Turchia 26
AT - Austria 24
NL - Olanda 24
PK - Pakistan 22
CO - Colombia 21
ID - Indonesia 18
CL - Cile 15
EC - Ecuador 15
VE - Venezuela 15
SA - Arabia Saudita 14
MA - Marocco 13
LT - Lituania 12
PH - Filippine 12
AL - Albania 10
BE - Belgio 10
EG - Egitto 10
GR - Grecia 9
UZ - Uzbekistan 9
IR - Iran 8
PY - Paraguay 8
TN - Tunisia 8
CZ - Repubblica Ceca 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
AZ - Azerbaigian 6
BO - Bolivia 6
BG - Bulgaria 5
ET - Etiopia 5
MY - Malesia 5
UY - Uruguay 5
CH - Svizzera 4
DZ - Algeria 4
JO - Giordania 4
KE - Kenya 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LV - Lettonia 4
MU - Mauritius 4
PE - Perù 4
PT - Portogallo 4
TH - Thailandia 4
AM - Armenia 3
DK - Danimarca 3
IL - Israele 3
KR - Corea 3
LB - Libano 3
RO - Romania 3
CR - Costa Rica 2
EU - Europa 2
HR - Croazia 2
JM - Giamaica 2
KH - Cambogia 2
KW - Kuwait 2
LU - Lussemburgo 2
MN - Mongolia 2
NG - Nigeria 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
Totale 10.096
Salva come PNG Salva come JPEG
Città #
Dublin 665
Chandler 522
Singapore 448
Ashburn 420
Hong Kong 417
San Jose 405
Dallas 374
Beijing 275
Nanjing 143
Los Angeles 137
Ho Chi Minh City 132
Helsinki 131
Lauterbourg 124
Johannesburg 121
Boardman 118
Jacksonville 105
Princeton 98
Lawrence 93
Hanoi 90
Munich 84
Medford 82
New York 80
Wilmington 70
Pavia 63
Nanchang 59
Redondo Beach 54
Shanghai 53
Buffalo 52
Moscow 42
Council Bluffs 41
Shenyang 39
Hebei 38
Milan 38
São Paulo 37
Changsha 35
Ann Arbor 34
Tokyo 34
Jiaxing 32
Turku 32
Orem 31
Piscataway 30
Montreal 29
Tianjin 28
Warsaw 28
Frankfurt am Main 27
Chennai 26
Nuremberg 26
Chicago 25
Denver 25
Norwalk 25
London 24
Da Nang 23
Santa Clara 23
Hangzhou 21
Haiphong 19
Houston 19
Seattle 19
Stockholm 19
Falkenstein 17
San Francisco 17
Guangzhou 15
Mexico City 15
Poplar 15
Toronto 15
Woodbridge 15
Pune 14
The Dalles 14
Atlanta 13
Manchester 13
Rio de Janeiro 13
Washington 13
Amsterdam 12
Ankara 12
Brooklyn 12
Baghdad 11
Boston 11
Induno Olona 11
Vienna 11
Brussels 10
Brasília 9
Fairfield 9
Hyderabad 9
Tirana 9
Zhengzhou 9
Biên Hòa 8
Cairo 8
Phoenix 8
Querétaro 8
Athens 7
Charlotte 7
Dhaka 7
Düsseldorf 7
Marseille 7
Medellín 7
Tamm 7
Tashkent 7
Turin 7
Vistarino 7
Baku 6
Belo Horizonte 6
Totale 6.722
Salva come PNG Salva come JPEG
Nome #
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 147
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 127
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 127
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 125
A patient with AL amyloidosis with negative free light chain results 123
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 122
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 120
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 119
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 119
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 119
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 118
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 118
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 118
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 116
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 115
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 114
A practical approach to the diagnosis of systemic amyloidoses 114
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 110
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 110
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 108
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 108
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 106
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 105
Prognostication of survival and progression to dialysis in AA amyloidosis 105
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 104
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 103
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 102
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis 102
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 101
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 100
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 100
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 99
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis 99
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 98
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 98
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 98
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 97
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 97
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 96
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 95
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 93
Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies 93
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 91
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy 91
A case of monoclonal gammopathy of renal significance 91
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 89
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 89
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 88
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis 88
Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. 87
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient 87
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis 86
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 86
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 83
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 83
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 82
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib and dexamethasone 81
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 81
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 80
Development and Validation of Staging Systems for AA Amyloidosis 79
La rilevanza diagnostica e prognostica del peptide natriuretico di tipo B (BNP) e del suo frammento N terminale (NT-proBNP) nei pazienti con amiloidosi AL e insufficienza renale 79
The lung in amyloidosis 78
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 78
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 77
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 76
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 75
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts 75
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 75
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 73
Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions 73
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 72
Attitudes about when and how to treat patients with AL amyloidosis: an international survey 72
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 71
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 71
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. 71
Management of AL amyloidosis in 2020 68
A powerful oral triplet for AL amyloidosis 67
HeLLePhant: A phantom mimicking non-small cell lung cancer for texture analysis in CT images 66
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 66
The use of mass spectrometry for the diagnosis of plasma cell dyscrasias: focus on light chain (AL) amyloidosis patterns. 63
Predicting survival in light chain amyloidosis 63
Nonbiopsy diagnosis of cardiac transthyretin amyloidosis 63
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 62
Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation 62
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis 62
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance 62
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 61
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 60
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis 60
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study 57
Conventional Therapy for Amyloid Light-Chain Amyloidosis 56
Monoclonal IgM-related AL amyloidosis 56
N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma 55
Management of AL amyloidosis in 2020 55
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 54
Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients 54
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 53
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 53
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 52
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 51
Totale 8.727
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.411
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.411
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202137 0 0 0 0 0 0 0 0 0 19 14 4
2021/2022413 5 2 12 0 12 6 6 33 24 21 54 238
2022/20231.570 166 141 20 87 110 135 14 83 753 11 33 17
2023/2024678 81 139 32 51 61 135 17 37 6 25 49 45
2024/20251.899 49 123 32 49 22 159 131 90 473 94 234 443
2025/20264.725 341 330 464 651 760 213 896 282 507 281 0 0
Totale 10.368